Kidney Transplantation From Donors with Resectable Renal Cell Carcinoma: Two Case Reports

Abstract Context: Primary aldosteronism (PA) is the most common cause of secondary hypertension. Aldosterone excess can cause DNA damage in vitro and in vivo. Single case reports have indicated a coincidence of PA with renal cell carcinoma and other tumors. However, the prevalence of benign and malignant neoplasms in patients with PA has not yet been studied. Patients and Design: In the multicenter MEPHISTO study, the prevalence of benign and malignant tumors was investigated in 335 patients with confirmed PA. Matched hypertensive subjects from the population-based Study of Health in Pomerania cohort served as controls. Results: Of the 335 PA patients, 119 (35.5%) had been diagnosed with a tumor at any time, and 30 had two or more neoplasms. Lifetime malignancy occurrence was reported in 9.6% of PA patients compared to 6.0% of hypertensive controls (P = .08). PA patients with a history of malignancy had higher baseline aldosterone levels at diagnosis of PA (P = .009), and a strong association between aldosterone levels and the prevalence of malignancies was observed (P = .03). In total, 157 neoplasms were identified in the PA patients; they were benign in 61% and malignant in 25% of the cases (14% of unknown dignity). Renal cell carcinoma was diagnosed in five patients (13% of all malignancies) and was not reported in controls. Conclusion: Compared to hypertensive controls, the prevalence of malignancies was positively correlated with aldosterone levels, tended to be higher in PA patients, but did not differ significantly.

Download Full-text

Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports

Experimental and Therapeutic Medicine ◽

10.3892/etm.2018.5882 ◽

2018 ◽

Author(s):

Hisashi Takeuchi ◽

Naoto Tokuyama ◽

Isao Kuroda ◽

Teiichiro Aoyagi

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Targeted Therapies ◽

Renal Cell ◽

Case Reports ◽

Life Stage ◽

Molecular Targeted Therapies

Download Full-text

Hereditary leiomyomatosis and renal cell carcinoma: a case series and literature review

Orphanet Journal of Rare Diseases ◽

10.1186/s13023-020-01653-9 ◽

2021 ◽

Vol 16 (1) ◽

Author(s):

Zahraa Chayed ◽

Lone Krøldrup Kristensen ◽

Lilian Bomme Ousager ◽

Karina Rønlund ◽

Anette Bygum

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Case Reports ◽

Case Series ◽

Surveillance Program ◽

Uterine Leiomyosarcoma ◽

Dermatological Examination ◽

The Mean ◽

Hereditary Leiomyomatosis

Abstract Background Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genodermatosis characterized by cutaneous leiomyoma (CLM), uterine leiomyoma (ULM) and renal cell carcinoma (RCC). Five HLRCC patients are presented with a compiled database of published HLRCC cases to increase understanding of HLRCC. Furthermore, a surveillance program is suggested. Our review is based on a PubMed search which retrieved case reports and cohort studies published before November 2019. The search yielded 97 original papers with a total of 672 HLRCC patients. Results CLMs were present in 474 patients (71.5%), developed at the mean age of 28 years. Five patients had cutaneous leiomyosarcomas. ULMs were present in 356 women (83%), while two had uterine leiomyosarcoma. ULMs were diagnosed at a mean age of 32 years, with the youngest diagnosed at age 17 years. The most common surgical treatment for ULMs was hysterectomy, performed at a mean age of 35 years, with the youngest patient being 19 years old. RCCs were present in 189 patients (34.9%), of which half had metastatic disease. The mean age of diagnosis was 36 years with the youngest patient diagnosed with RCC at the age of 11 years. Conclusion We suggest a surveillance program for HLRCC including a dermatological examination once every 2 years, annual magnetic resonance imaging starting at the age of 10 years to monitor for early RCCs, annual gynecological examinations from the age of 15 years and counseling regarding risk of hysterectomy and family planning at the age of 18 years. CLMs are often the earliest manifestation of HLRCC, which is why recognizing these lesions, performing a biopsy, and making a prompt referral to genetic counseling is important in order to diagnose HLRCC early.

Download Full-text

Concurrent renal cell carcinoma and hematologic malignancies: Nine case reports

World Journal of Clinical Oncology ◽

10.5306/wjco.v11.i8.644 ◽

2020 ◽

Vol 11 (8) ◽

pp. 644-654

Author(s):

Lisa BE Shields ◽

Arash Rezazadeh Kalebasty

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Case Reports ◽

Hematologic Malignancies

Download Full-text

Studying the Association Between Breast Cancer and Renal Cell Carcinoma

10.21203/rs.3.rs-841536/v1 ◽

2021 ◽

Author(s):

Khalid A Jazieh ◽

Firas Baidoun ◽

Nataly Torrejon ◽

Zahi Merjaneh ◽

Anas Saad ◽

...

Keyword(s):

Breast Cancer ◽

Renal Cell Carcinoma ◽

Genetic Testing ◽

Family History ◽

Cell Carcinoma ◽

Renal Cell ◽

Case Reports ◽

Population Data ◽

Seer Database ◽

History Of

Abstract Purpose: There are case reports of patients with both primary breast cancer (BC) and renal cell carcinoma (RCC). We explore the association between these two malignancies using SEER population data and our institutional records.Methods: We studied the association between BC and RCC in the 2000-2016 Surveillance, Epidemiology and End Results (SEER) database. We then reviewed our hospital records of patients with both BC and RCC and collected information including personal and family history of cancers, genetic testing, and patient outcomes.Results: Of the 813,477 females diagnosed with BC in the SEER database, 1,914 later developed RCC. The risk of developing RCC was significantly increased within the first six months, 7-12 months, and 1-5 years following BC diagnosis with standardized incidence ratios (SIRs) of 5.08 (95% CI, 4.62- 5.57), 2.09 (95% CI, 1.8-2.42), and 1.15 (95% CI, 1.06-1.24), respectively. Of 56,200 females with RCC, 1,087 later developed BC. The risk of developing BC following RCC was elevated within the first six months (SIR of 1.45 [95% CI, 1.20-1.73]). For our hospital patients, 437 had both BC and RCC. 427 (97.71%) were female, and 358 (81.92%) were white, and breast cancer was diagnosed before RCC in 246 (61.5%) patients. There were 15 germline mutations in those with genetic testing. Conclusion:Our findings suggest that BC patients are at higher risk of developing RCC and vice versa. BC tended to precede RCC, and patients frequently had personal histories of other malignancies and a family history of cancer, particularly BC.

Download Full-text